Molecular Imaging

Global Molecular Imaging Market to Reach US$10.4 Billion by 2030

The global market for Molecular Imaging estimated at US$8.6 Billion in the year 2024, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Single Photon Emission Computed Tomography Modality, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Positron Emission Tomography Modality segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 6.1% CAGR

The Molecular Imaging market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Molecular Imaging Market – Key Trends & Drivers Summarized

How Is Molecular Imaging Revolutionizing Precision Medicine and Early Disease Detection?

Molecular imaging has emerged as a cornerstone technology in modern healthcare, offering unparalleled insights into biological processes at the molecular and cellular levels. Unlike traditional imaging modalities that primarily focus on anatomical structures, molecular imaging provides functional and metabolic information that aids in early disease detection, staging, and personalized treatment planning. The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions has intensified the need for more precise diagnostic tools. Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and hybrid imaging techniques such as PET-CT and PET-MRI have transformed diagnostic workflows by enabling real-time tracking of disease progression and treatment response. The growing integration of radiopharmaceuticals, which serve as biomarkers for targeted imaging, is further enhancing diagnostic accuracy and patient outcomes. As the demand for non-invasive and early detection methods rises, molecular imaging continues to gain widespread adoption across hospitals, research institutions, and pharmaceutical industries, reinforcing its pivotal role in precision medicine.

What Technological Advancements Are Driving the Molecular Imaging Market?

The molecular imaging market is witnessing a rapid transformation, driven by continuous advancements in imaging modalities, artificial intelligence (AI), and radiopharmaceuticals. AI-powered imaging analytics have enabled faster and more precise interpretation of complex imaging data, reducing diagnostic errors and improving clinical decision-making. Additionally, the development of novel radiotracers targeting specific biomarkers has significantly enhanced the sensitivity and specificity of molecular imaging techniques. Hybrid imaging systems, such as PET-CT and SPECT-CT, have further refined the diagnostic landscape by providing integrated functional and anatomical insights in a single scan, thereby improving efficiency and patient comfort. The rise of optical and fluorescence-based molecular imaging is expanding applications in oncology and neurology, enabling researchers to visualize molecular activity in real-time. Moreover, miniaturized and portable molecular imaging devices are being developed to facilitate point-of-care diagnostics, particularly in resource-limited settings. As technology continues to evolve, the convergence of AI, machine learning, and next-generation imaging agents is expected to redefine the molecular imaging market, unlocking new possibilities for disease management and treatment optimization.

How Is Regulatory and Market Dynamics Influencing Molecular Imaging Adoption?

Regulatory frameworks and market dynamics play a crucial role in shaping the growth of the molecular imaging sector. Stringent guidelines governing the approval and distribution of radiopharmaceuticals and imaging devices necessitate continuous innovation to meet safety and efficacy standards. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have imposed rigorous compliance measures to ensure the reliability and ethical use of molecular imaging technologies. At the same time, increasing investments from governments, healthcare institutions, and private entities are driving research and development initiatives in this space. The growing trend of public-private partnerships is facilitating the expansion of molecular imaging infrastructure in emerging economies, broadening access to advanced diagnostic services. Additionally, reimbursement policies for imaging procedures significantly impact market adoption, with favorable reimbursement models encouraging wider clinical utilization. Furthermore, the pharmaceutical industry`s reliance on molecular imaging for drug development and clinical trials is reinforcing the sector’s market potential. As regulatory landscapes continue to evolve, aligning innovation with compliance will be essential in sustaining market growth and expanding the accessibility of molecular imaging solutions.

What Are the Key Factors Fueling the Growth of the Molecular Imaging Market?

The growth in the global molecular imaging market is driven by several factors, including rising disease burden, technological advancements, regulatory support, and increasing research investments. The growing incidence of cancer, cardiovascular diseases, and neurological disorders has amplified the need for early and accurate diagnosis, positioning molecular imaging as a critical tool in modern healthcare. Innovations in radiopharmaceuticals, AI-driven imaging analytics, and hybrid imaging systems have significantly enhanced diagnostic precision, leading to wider adoption across medical and research applications. The expansion of personalized medicine and targeted therapy approaches is also boosting demand for molecular imaging, as it enables tailored treatment strategies based on individual patient profiles. Additionally, increasing healthcare expenditures in emerging economies and the expansion of imaging infrastructure are driving market penetration in underserved regions. The pharmaceutical and biotechnology industries` dependence on molecular imaging for drug discovery, biomarker validation, and clinical trial monitoring is another key growth accelerator. Moreover, ongoing research into non-invasive imaging techniques and next-generation tracers is expected to expand the scope of molecular imaging applications. As healthcare systems worldwide prioritize early disease detection and precision medicine, the molecular imaging market is poised for sustained expansion, offering new opportunities for industry stakeholders and researchers alike.

SCOPE OF STUDY:

The report analyzes the Molecular Imaging market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Modality (Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality, Other Modalities); Application (Oncology Application, Cardiovascular Application, Neurology Application, Respiratory Application, Other Applications); End-Use (Hospitals End-Use, Diagnostic Imaging Centers End-Use, Research Institutes End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Abbott Laboratories
• Bio-Rad Laboratories
• Bruker Corporation
• Canon Medical Systems Corporation
• Cubresa Inc.
• Esaote
• GE HealthCare
• Koninklijke Philips N.V.
• Mediso
• PerkinElmer
• PerkinElmer Inc.
• Positron Corporation
• QIAGEN
• Roche Diagnostics
• Shimadzu Corporation
• Siemens AG
• Siemens Healthineers
• Thermo Fisher Scientific
• United Imaging Healthcare Co.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.